Literature DB >> 19725511

Regulating the conformation of prion protein through ligand binding.

Norifumi Yamamoto, Kazuo Kuwata.   

Abstract

Although some antiprion compounds have been shown to interfere with the pathological conversion of prion protein into a misfolded isoform, the actual mechanism has not been elucidated. In this study, we compared different conformations of prion protein with and without ligand binding, based on molecular dynamics simulations, to clarify the role of a typical antiprion compound termed GN8. In our approach, urea-driven unfolding simulations were employed to assay whether or not GN8 prevents denaturation of prion protein. We found that urea mediates partial unfolding at helix B of the prion protein, suggesting a transition into the intermediate states of the pathological conversion. However, GN8 efficiently suppressed local fluctuations by binding to flexible spots on helix B and prevented its urea-induced denaturation. We conclude that GN8 inhibits pathological conversion by suppressing the level of the intermediate. This is the first evidence supporting the chemical chaperone hypothesis, which states that GN8 acts as a chaperone to stabilize the normal form of the prion protein. Our basic principle constitutes a promising strategy for a dynamics-based drug design of therapeutic compounds, particularly for prion diseases and other diseases related to protein misfolding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725511     DOI: 10.1021/jp905572w

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  7 in total

1.  A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Authors:  N C Ferreira; L M Ascari; A G Hughson; G R Cavalheiro; C F Góes; P N Fernandes; J R Hollister; R A da Conceição; D S Silva; A M T Souza; M L C Barbosa; F A Lara; R A P Martins; B Caughey; Y Cordeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  Therapeutic strategies for identifying small molecules against prion diseases.

Authors:  Elisa Uliassi; Lea Nikolic; Maria Laura Bolognesi; Giuseppe Legname
Journal:  Cell Tissue Res       Date:  2022-01-06       Impact factor: 5.249

3.  Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.

Authors:  Daisuke Ishibashi; Takeshi Ishikawa; Satoshi Mizuta; Hiroya Tange; Takehiro Nakagaki; Tsuyoshi Hamada; Noriyuki Nishida
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.

Authors:  Yuji O Kamatari; Yosuke Hayano; Kei-ichi Yamaguchi; Junji Hosokawa-Muto; Kazuo Kuwata
Journal:  Protein Sci       Date:  2012-11-19       Impact factor: 6.725

5.  Insight into Early-Stage Unfolding of GPI-Anchored Human Prion Protein.

Authors:  Emilia L Wu; Yifei Qi; Soohyung Park; Sairam S Mallajosyula; Alexander D MacKerell; Jeffery B Klauda; Wonpil Im
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

6.  Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target.

Authors:  Massimiliano Meli; Maria Gasset; Giorgio Colombo
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

7.  Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.

Authors:  Jae Wook Hyeon; Jiwon Choi; Su Yeon Kim; Rajiv Gandhi Govindaraj; Kyu Jam Hwang; Yeong Seon Lee; Seong Soo A An; Myung Koo Lee; Jong Young Joung; Kyoung Tai No; Jeongmin Lee
Journal:  Sci Rep       Date:  2015-10-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.